These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25855484)

  • 21. Update on treatment regimens: prophylaxis versus on-demand therapy.
    Manco-Johnson MJ
    Semin Hematol; 2003 Jul; 40(3 Suppl 3):3-9. PubMed ID: 14690062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of hemophilia].
    Straub PW
    Dtsch Med Wochenschr; 1969 Sep; 94(37):1885-7. PubMed ID: 5356323
    [No Abstract]   [Full Text] [Related]  

  • 24. Switching to extended half-life products in Canada - preliminary data.
    Keepanasseril A; Stoffman J; Bouskill V; Carcao M; Iorio A; Jackson S;
    Haemophilia; 2017 Jul; 23(4):e365-e367. PubMed ID: 28548284
    [No Abstract]   [Full Text] [Related]  

  • 25. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
    Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
    Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Substitution treatment in hemophilia. Critical measures and complications].
    Schimpf K
    Wien Med Wochenschr; 1977 Jun; 127(11):329-37. PubMed ID: 878496
    [No Abstract]   [Full Text] [Related]  

  • 27. Half-life extension technologies for haemostatic agents.
    Mannucci PM
    Thromb Haemost; 2015 Jan; 113(1):165-76. PubMed ID: 25274414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary prophylaxis with factor IX concentrates: continuous infusion.
    Morfini M
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s21-5. PubMed ID: 19105506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The availability of new drugs for hemophilia treatment.
    Morfini M; Marchesini E
    Expert Rev Clin Pharmacol; 2020 Jul; 13(7):721-738. PubMed ID: 32515633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting.
    Ay C; Perschy L; Rejtö J; Kaider A; Pabinger I
    Ann Hematol; 2020 Dec; 99(12):2763-2771. PubMed ID: 32918114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
    Morfini M; Farrugia A
    Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
    [No Abstract]   [Full Text] [Related]  

  • 34. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
    Schulte S
    Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
    von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
    Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
    Wu RH; Wu XY; Zhang NN; Zhao L; Zhang JS; Zhen YZ; Peng Y
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
    [No Abstract]   [Full Text] [Related]  

  • 38. Extended half-life clotting factor concentrates: results from published clinical trials.
    Young G; Mahlangu JN
    Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unresolved issues in prophylaxis.
    Brown SA; Aledort LM; Astermark J; Berntorp E; van den Berg M; Blanchette V; Donfield S; Gringeri A; Hilgartner M; Kulkarni R; Leissinger C; Negrier C; Nuss R; Petterson H; Petrini P; Poulios N; Schramm W;
    Haemophilia; 2002 Nov; 8(6):817-21. PubMed ID: 12410654
    [No Abstract]   [Full Text] [Related]  

  • 40. Hemophilia Foundation recommends prophylactic use of clotting factors.
    Skolnick AA
    JAMA; 1994 Oct; 272(15):1153-4. PubMed ID: 7933330
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.